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Although historically a genetically intractable bacterium, Chlamydia is experiencing a renaissance for molec-
ular genetic manipulation. Two new studies published in Cell Host & Microbe, Mirrashidi et al. (2015) and
Kokes et al. (2015), have dramatically changed the landscape of what is possible for molecular dissection
of Chlamydia-host interactions.Chlamydia trachomatis is the etiological
agent of both sexually transmitted dis-
ease as well as ocular infections resulting
in blindness. C. trachomatis continues to
elicit a major burden on global human
health, due to the chronic nature of infec-
tion and the lack of an effective vaccine.
C. trachomatis targets mucosal epithelial
cells of the genital tract and conjuctiva
for intracellular growth, and alternates
between two developmental forms—an
infectious but metabolically inert elemen-
tary body (EB) and a replicative reticulate
body (RB). A source of great historical
frustration for the Chlamydia research
community has been the intractability of
this bacterium to classical and modern
genetic manipulations. Key obstacles
include its obligate intracellular nature,
such that these bacteria cannot be
grown axenically, a minimal and highly
conserved genome throughout the genus,
and a biphasic developmental cycle.
Recent years have heralded a series of
breakthroughs that are rapidly eroding the
notion that Chlamydia are genetically
intractable and have transformed the
landscape of Chlamydia research by ush-
ering in powerful new tools to study its
pathogenesis. Two recent studies in
Cell Host & Microbe have raised the bar
even higher, by providing roadmaps for
genome-wide screens (Kokes et al.,
2015) and secreted effector proteomics
(Mirrashidi et al., 2015).
The historical framework of Chlamydia
research provides a context in which to
appreciate the accelerating pace of chla-
mydial molecular genetics in recent years
(Figure 1). The earliest characterization of
Chlamydia-like organisms came in the
early 1930s, when Bedson and Bland
described the two developmental forms
of the ‘‘psittacosis virus.’’ Reclassification
of the pathogen as a bacterium, andnaming the organism Chlamydia, did not
occur until the early 1960s.
The genomic age of Chlamydia
research began in earnest in 1998 when
Stephens and colleagues sequenced the
first Chlamydia genome, C. trachomatis
D/UW3 (Stephens et al., 1998). This
landmark achievement revealed a small,
highly conserved genome and fueled
genomic comparisons between various
clinical C. trachomatis isolates and other
members of the genus. The next major
advances came with the discoveries that
both lateral gene transfer among Chla-
mydia strains and stable incorporation
of recombinant DNA containing select-
able-resistance markers into the Chla-
mydia chromosome were experimentally
possible (Demars et al., 2007; Binet and
Maurelli, 2009). Further reports have since
suggested that recombination among
C. trachomatis strains in vivo is more
prevalent than previously assumed and
that the classically designated serotypes
of C. trachomatis may actually be in con-
stant states of genetic flux.
In 2011, Wang and Clarke reported the
watershed discovery of a shuttle vector
and a stable system for genetic transfor-
mation of C. trachomatis (Wang et al.,
2011). As expected, widespread adapta-
tion of this system by the field has accel-
erated discoveries regarding chlamydial
gene function and the role of the cryptic
plasmid in pathogenesis. In addition,
several research groups have built on
this technology to engineer new sys-
tems for modulating gene function. For
example, in 2013, Hefty and colleagues
developed an inducible gene expression
system for Chlamydia (Wickstrum et al.,
2013), and Johnson and Fisher (2013)
adapted a mobile group II intron system
to perform the first targeted inactivation
of a chromosomal gene in Chlamydia.Cell Host & MicroConcurrent with these milestones, par-
allel advances were made toward exploit-
ing chemical mutagenesis as a platform
for investigating single gene function in
Chlamydia. In 2011, Kari et al. (2011)
demonstrated that the targeted induced
local lesions in genomes (TILLING)
screening strategy could be used to
generate and select pools of Chlamydia
mutants harboring SNPs in a non-essen-
tial gene of interest, without the need for
antibiotic selection.
Recently, in Cell Host & Microbe, Kokes
et al. (2015) provided a thorough descrip-
tion of how libraries of chemically muta-
genized C. trachomatis can be generated,
genotypedbywhole-genomesequencing,
and subjected to forward genetic screens
for discrete phenotypes. This strategy
currently represents the gold standard for
genome-wide screening in Chlamydia, as
insertional disruption using transposons
is not yet possible, and gene inactivation
by mobile introns has yet to be scaled up
to cover the entire genome. Furthermore,
chemical mutagenesis offers numerous
advantages including the ability to impair
single genes within operons without polar
effects, and the possibility of both gain-
of-function mutants, as well as hypomor-
phic mutations that perturb enzymatic
function of otherwise essential genes.
Finally, the financial barriers to genome-
wide screens are plummeting, aided by
the dropping costs of next-generation
sequencing, the smallChlamydia genome,
and the high conservation and lack of
repeat sequences that could otherwise
confound bioinformatic analysis.
The Kokes et al. study further demon-
strated how forward genetic screens
could be conducted in C. trachomatis, in
a manner that fulfills Koch’s molecular
postulates. Phenotypic screening identi-
fied a mutant that failed to polymerizebe 18, July 8, 2015 ª2015 Elsevier Inc. 11
Figure 1. Milestones in Chlamydia Genetics and Proteomics
Chlamydia-like organisms, and their developmental forms, were first reported by Bedson and Bland in the
1930s. The organism was finally classified as a bacterium, after much debate, in the 1960s; also at this
time, the species name Chlamydia trachomatis was established. Milestone advances in Chlamydia ge-
netics include: sequencing of the first Chlamydia genome by Stephens et al. (1998); demonstration of
lateral gene transfer and recombination by Demars et al. (2007); transformation ofC. psittaci and antibiotic
selection of recombinants by Binet and Maurelli (2009); establishment of a system for stable plasmid-
based transformation of C. trachomatis by Wang et al. (2011); forward genetics by chemical mutagenesis
by Kari et al. (2011) and Nguyen and Valdivia in 2012; generation of an inducible gene expression system
for Chlamydia by Wickstrum et al. (2013); reverse genetics using site-specific mobile introns by Johnson
and Fisher (2013); and forward genetic screening of sequenced C. trachomatismutant libraries by Kokes
et al. (2015). Key advances in Chlamydia proteomics include: proteomic analysis of C. trachomatis EB by
Shaw et al. in 2002; quantitative proteomic analysis of C. trachomatis RB and EB by Saka et al. (2011);
global analysis of host protein stability during Chlamydia infection by Olive et al. in 2014; proteomic anal-
ysis of isolated C. trachomatis vacuoles by Aeberhard et al. in 2015; and identification of host interaction
partners for C. trachomatis Inc proteins by Mirrashidi et al. (2015).
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This strain harbored 12 non-synonymous
SNPs within its genome (Kokes et al.,
2015), and lateral gene transfer from the
mutant strain to a wild-type parent re-
vealed an association between a
nonsense mutation in gene CT813 (InaC)
and the actin-recruitment phenotype.
The causal role of this SNP was demon-
strated by trans-complementation of the
mutant with a plasmid-containing wild-
type CT813. The authors proceeded to
assign a functional role for IncC in recruit-
ing ARF and 14-3-3 family proteins, and
the Golgi, to the chlamydial vacuole
(inclusion).
Technological advances in mass spec-
trometry-based proteomics two decades
ago made possible a series of studies
focused on identifying the protein expres-
sion profiles of Chlamydia. These efforts
culminated with a report by Saka and col-
leagues in 2011, wherein the proteomes
of the two developmental forms of Chla-
mydia, the EB and RB, were analyzed by12 Cell Host & Microbe 18, July 8, 2015 ª201quantitative mass spectrometry (Saka
et al., 2011). Highlights of this study
were the findings that EB were enriched
in proteins necessary for glucose catabo-
lism and central metabolism, thus sug-
gesting that EB are poised to elicit a burst
of metabolic activity upon entry into host
cells. Chlamydia RB, on the other hand,
expressed high levels of proteins involved
with protein synthesis, ATP production,
and nutrient transport, consistent with
their role in bacterial replication.
The obligate intracellular nature of
Chlamydia and its possession of special-
ized secretion systems are indicative of
the bacterium’s need to secrete proteins
that manipulate host-cell signaling. How-
ever, the biological and evolutionary
sequestration of C. trachomatis from
other bacteria has precluded identifica-
tion of candidate effectors from genomic
data. The inclusion membrane serves as
the gateway to Chlamydia’s ability to
interact with proteins in the host cell. In
accordance with the importance of this5 Elsevier Inc.membrane, C. trachomatis encodes 62
predicted inclusion membrane (Inc) pro-
teins, accounting for nearly 7% of its pro-
tein-coding genes. The striking variety of
Inc proteins across Chlamydia species,
the sequence diversity of Incs among
clinical C. trachomatis strains, and their
uniqueness for Chlamydia, strongly
argue for their involvement in defining
the chlamydial inclusion and responsive-
ness to selective pressures. Yet, little
data exists for the functional roles of Inc
proteins during infection.
In this issue of Cell Host & Microbe,
Mirrashidi et al. (2015) undertook a
massive effort to comprehensively iden-
tify protein-protein interactions between
predicted C. trachomatis Incs and the
host proteome. The authors cloned 58
predicted C. trachomatis Incs with affin-
ity tags, ectopically expressed them in
mammalian cells, and subjected affin-
ity-purified protein lysates to mass spec-
trometry. From the resulting data, 354
high confidence Inc-host-protein inter-
actions were identified, with host targets
spanning a wide range of cellular path-
ways. The extent of host-protein interac-
tions and the segregation of those inter-
actions into discrete clusters have, in
turn, illuminated host-cell processes
that Chlamydia has evolved to exploit.
Mirrashidi et al. (2015) proceeded to
investigate in more detail the interaction
of IncE with sorting nexins 5 and 6, key
components of the retromer complex.
This interaction was revealed to disrupt
homeostatic retromer trafficking and
thus to promote a favorable growth envi-
ronment for Chlamydia.
What does the future hold? On the near
horizon, proteomic approaches will
continue to yield insights, and additional
modern genetic tools such as transpo-
sons, CRISPR, recombinase systems,
and temperature sensitive mutants, will
undoubtedly be adapted for use in Chla-
mydia. However, these advances are un-
likely to be revolutionary on their own, in
large part due to the minimal, conserved
genome of Chlamydia. Rather, it will be
the application of genetic strategies to
particular questions that will fuel major
discoveries in Chlamydia biology and
pathogenesis; for example, studies identi-
fying collections of chlamydial genes
essential and nonessential for growth
in vitro, and genes that correlate directly
with virulence in the infected host.
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